TNFRSF17 and Miyoshi myopathy: We next examined the efficacy of GSI treatment in BCMA-knockdown (KD) H929-KD and U266-KD MM cells (~39- and 4-fold lower mBCMA, compared with their respective parental cells, Fig. 1E, left).